{
    "body": "Why does the prodrug amifostine (ethyol) create hypoxia?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23154884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17852557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11597323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20334641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17602063", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11984063", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11379297", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8976819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19182669", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14574457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21590129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11712796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8783669"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17889382", 
            "o": "N0000022033"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1874179", 
            "o": "http://linkedlifedata.com/resource/umls/label/A17889382"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17889382", 
            "o": "AMIFOSTINE/MANNITOL"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1874179", 
            "o": "http://linkedlifedata.com/resource/umls/label/A12102802"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1874179", 
            "o": "http://linkedlifedata.com/resource/umls/label/A17985952"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17985952", 
            "o": "N0000022033"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A12102802", 
            "o": "4024028"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A10414743", 
            "o": "330576"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A10414743", 
            "o": "Amifostine 50 MG/ML"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1126264", 
            "o": "http://linkedlifedata.com/resource/umls/label/A10414743"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#note", 
            "s": "http://linkedlifedata.com/resource/umls/label/A10488633", 
            "o": "RXNORM"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1251303", 
            "o": "http://linkedlifedata.com/resource/umls/label/A10488633"
        }, 
        {
            "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1251303", 
            "o": "http://linkedlifedata.com/resource/umls/label/A10488633"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A10488633", 
            "o": "Amifostine Injectable Solution"
        }
    ], 
    "ideal_answer": [
        "After the administration of Prodrug amifostine the cells of the tissue prefer anaerobic glycolysis rather than regular cellular aerobic respiration. By the beggining of anaerobic glycolysis the inducible by hypoxia proteins are induced and by all these molecules  the hypoxic conditions consist of."
    ], 
    "concepts": [
        "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0071456", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004999", 
        "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001666", 
        "http://www.biosemantics.org/jochem#4217067", 
        "http://www.biosemantics.org/jochem#4277891", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000860", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015687"
    ], 
    "type": "summary", 
    "id": "533eba45c45e133714000014", 
    "snippets": [
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 261, 
            "text": "Amifostine (WR-2721, delivered as Ethyol) is a phosphorylated aminothiol compound clinically used in addition to cis-platinum to reduce the toxic side effects of therapeutic treatment on normal cells without reducing their efficacy on tumour cells. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 392, 
            "offsetInEndSection": 671, 
            "text": "However, amifostine has also been described as a potent hypoxia-mimetic compound and as a strong p53 inducer; both effects are known to potently modulate vascular endothelial growth factor (VEGF-A) expression. The angiogenic properties of this drug have not been clearly defined.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 869, 
            "offsetInEndSection": 1158, 
            "text": "Both dose fractionation and amifostine protect osteoblasts from the growth inhibitory effects of ionizing radiation. Fractionation but not amifostine was protective for hypoxia-induced vascular endothelial growth factor production (used as a surrogate marker of normal osteoblast function)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19182669", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 451, 
            "text": "Radioprotective modalities such as dose fractionation and pharmacologic agents such as amifostine have been used to protect bone and other types of normal tissue from the damaging effects of ionizing radiation without significantly impacting tumor kill. To better understand the cellular mechanism of radioprotection of osseous tissue, the authors sought to determine the effect of dose fractionation and amifostine on isolated osteoblasts", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19182669", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 364, 
            "text": "Tumor hypoxia and low intrinsic radiosensitivity may counteract the efficacy of standard radiotherapy for locally advanced head and neck cancer (HNC). We investigated the involvement of hypoxia-regulated proteins (Hypoxia inducible factors HIF1alpha, HIF2alpha and carbonic anhydrase CA9) in HNC resistance to accelerated and hypofractionated radiotherapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17852557", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 671, 
            "offsetInEndSection": 864, 
            "text": " Immunohistochemical analysis of hypoxia-regulated proteins, namely HIF1alpha, HIF2alpha and CA9, was performed in formalin-fixed paraffin-embedded tissues obtained prior to radio-chemotherapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17852557", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1509, 
            "offsetInEndSection": 1867, 
            "text": "In accord with previously reported studies, high levels of the hypoxia regulated proteins HIF1alpha and CA9 in HNC predict resistance to platinum based radio-chemotherapy. Whether HIF2alpha expressing tumors are more sensitive to larger radiotherapy fractions, compared to standard radiotherapy fractionation, is an issue that deserves further investigation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17852557", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 149, 
            "offsetInEndSection": 760, 
            "text": "Amifostine has been shown to specifically protect normal tissues from damage caused by radiation and chemotherapy. An inactive prodrug, amifostine is converted to an active thiol by dephosphorylation by alkaline phosphatase in the normal endothelium. The hypovascularity and acidity of the tumor environment and the differential expression of alkaline phosphatase in normal and neoplastic tissues contribute to its cytoprotective selectivity. The cytoprotective mechanism of amifostine is complicated, involving free-radical scavenging, DNA protection and repair acceleration, and induction of cellular hypoxia.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17602063", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 121, 
            "offsetInEndSection": 389, 
            "text": "We investigated additional cytoprotective pathways involving intracellular hypoxia and the activation of the hypoxia-inducible factor (HIF) pathway, a key transcription factor regulating glycolysis, angiogenesis and apoptosis, which is also linked with radioresistance", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574457", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 587, 
            "text": " tumor hypoxia and ability of cancer cells to undergo rapid repopulation during radiotherapy are associated with failure of radiotherapy. Tumors with low alpha/beta-ratio values or hypoxic tumors unable to undergo re-oxygenation, are unlikely to be eradicated with standard radiotherapy. Although the therapeutic efficacy of accelerated regimens based on low-dose per fraction may be high since they minimize the adverse role of rapid tumor repopulation, the cellular compartment with low alpha/beta-ratio values (i.e. hypoxic cells) remains a limiting factor. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11712796", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 367, 
            "offsetInEndSection": 878, 
            "text": "Amifostine (Ethyol) is a prodrug that must be dephosphorylated to the free thiol in which form it can detoxify free oxygen radicals generated by radiation, hypoxia and by drugs such anthracyclines, platinum analogues and alkylating agents. Amifostine as inactive prodrug is primarily metabolized at the tissue site by membrane alkaline phosphatase, which is highly active in the cell membranes of normal endothelial cells and biliary tree cells but not in the cell membranes and neovascular capillaries of tumor", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11379297", 
            "endSection": "abstract"
        }
    ]
}